-

CASSAVA SCIENCES INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Cassava Sciences, Inc. - SAVA

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigation into Cassava Sciences, Inc. (NasdaqCM: SAVA).

Beginning in August 2021, the Company was the subject of allegations of data manipulation and misrepresentation in the research underpinning its Alzheimer's drug, called simufilam. The Company issued a statement claiming that the clinical data had been generated by Quanterix Corp. (“Quanterix”), an independent company, implying that the reanalysis was objective and valid; however, Quanterix subsequently issued a statement denying the Company’s claims, stating that it “did not interpret the test results or prepare the data.” Then in November 2021, it was reported that the Securities and Exchange Commission had opened an investigation into the Company’s simufilam research. In July 2022, media sources reported that the U.S. Justice Department had also opened a criminal investigation into the matter.

The Company and certain of its executives have been sued in a securities class action lawsuit charging them with failing to disclose material information during the Class Period in violation of federal securities laws, which remains ongoing.

KSF’s investigation is focusing on whether Cassava’s officers and/or directors breached their fiduciary duties to its shareholders or otherwise violated state or federal laws.

If you have information that would assist KSF in its investigation, or have been a long-term holder of Cassava shares and would like to discuss your legal rights, you may, without obligation or cost to you, call toll-free at 1-877-515-1850 or email KSF Managing Partner Lewis Kahn (lewis.kahn@ksfcounsel.com), or visit https://www.ksfcounsel.com/cases/nasdaqcm-sava/ to learn more.

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms. KSF serves a variety of clients – including public institutional investors, hedge funds, money managers and retail investors – in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, California, Louisiana and New Jersey.

To learn more about KSF, you may visit www.ksfcounsel.com.

Contacts

Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
lewis.kahn@ksfcounsel.com
1-877-515-1850

Kahn Swick & Foti, LLC

NASDAQ:SAVA

Release Versions

Contacts

Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
lewis.kahn@ksfcounsel.com
1-877-515-1850

More News From Kahn Swick & Foti, LLC

Navan Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Navan, Inc. - NAVN

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Navan, Inc. (“Navan” or the “Company”) (NasdaqGS: NAVN).Navan, headquartered in Palo Alto, California, provides booking and expense management software for business travelers. On or about October 31, 2025, Navan conducted its initial public offering (the “IPO” or “Offering”), selling...

Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. - SRPT

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Sarepta Therapeutics, Inc. (NasdaqGS: SRPT) (“Sarepta” or the “Company”). Sarepta is a biopharmaceutical company focused on developing treatments for rare diseases. Sarepta's most important product is Elevidys, a therapy for the treatment of Duchenne muscular dystrophy. A...

Capital Bancorp Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Capital Bancorp, Inc. - CBNK

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Capital Bancorp, Inc. ("Capital") (NasdaqGS: CBNK) to Peoples Bancorp Inc. ("Peoples") (NasdaqGS: PEBO). Under the terms of the proposed transaction, shareholders of Capital will receive 1.11 shares of Peoples common stock for each share of Capital that they own. Upon closing of the proposed transac...
Back to Newsroom